Mutations Conferring Resistance to a Potent Hepatitis C Virus Serine Protease Inhibitor In Vitro
BILN 2061 is a novel, specific hepatitis C virus (HCV) NS3 serine protease inhibitor discovered by Boehringer Ingelheim that has shown potent activity against HCV replicons in tissue culture and is currently under clinical investigation for the treatment of HCV infection. The poor fidelity of the HC...
Kaydedildi:
| Yayımlandı: | Antimicrob Agents Chemother |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
American Society for Microbiology (ASM)
2004
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC415624/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/15155230/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.48.6.2260-2266.2004 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|